Wedbush restated their outperform rating on shares of SpringWorks Therapeutics (NASDAQ:SWTX – Free Report) in a report issued on Thursday,RTT News reports. They currently have a $77.00 price target on the stock. Several other research analysts have also issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $76.00 target price […]

AvidXchange (NASDAQ:AVDX – Free Report) had its target price hoisted by Keefe, Bruyette & Woods from $9.00 to $10.00 in a research report released on Thursday,Benzinga reports. They currently have a market perform rating on the stock. A number of other research firms have also recently weighed in on AVDX. The Goldman Sachs Group lowered […]

ARM (NASDAQ:ARM – Free Report) had its price objective lifted by Susquehanna from $115.00 to $118.00 in a report published on Thursday,Benzinga reports. Susquehanna currently has a neutral rating on the stock. A number of other research analysts have also recently issued reports on the stock. Raymond James initiated coverage on shares of ARM in […]

HC Wainwright reaffirmed their buy rating on shares of Keros Therapeutics (NASDAQ:KROS – Free Report) in a report issued on Thursday,Benzinga reports. They currently have a $100.00 price target on the stock. A number of other research firms also recently commented on KROS. Scotiabank initiated coverage on Keros Therapeutics in a research note on Wednesday, […]

Wedbush reaffirmed their outperform rating on shares of Monte Rosa Therapeutics (NASDAQ:GLUE – Free Report) in a report issued on Thursday,RTT News reports. The brokerage currently has a $15.00 target price on the stock. Separately, Wells Fargo & Company decreased their price objective on shares of Monte Rosa Therapeutics from $18.00 to $17.00 and set […]

HC Wainwright reiterated their buy rating on shares of LENZ Therapeutics (NASDAQ:LENZ – Free Report) in a research note published on Thursday,Benzinga reports. The brokerage currently has a $38.00 price target on the stock. Other equities analysts also recently issued reports about the company. Raymond James began coverage on LENZ Therapeutics in a report on […]

CSG Systems International (NASDAQ:CSGS – Get Free Report) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Thursday. Several other equities research analysts have also commented on CSGS. Wells Fargo & Company upped their price target on CSG Systems International from $43.00 […]

SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Wedbush in a report released on Thursday,RTT News reports. They presently have a $77.00 price target on the stock. Wedbush’s price objective would suggest a potential upside of 132.70% from the company’s current price. Several other analysts […]

Cytokinetics (NASDAQ:CYTK – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $120.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 112.80% from the stock’s current price. Several […]

National CineMedia, Inc. (NASDAQ:NCMI – Get Free Report) shares hit a new 52-week high on Tuesday . The company traded as high as $7.39 and last traded at $7.34, with a volume of 310604 shares traded. The stock had previously closed at $7.12. Wall Street Analysts Forecast Growth A number of brokerages have recently weighed […]

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They currently have a $27.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 70.99% from the stock’s current price. Several […]

HC Wainwright reiterated their neutral rating on shares of Arcus Biosciences (NYSE:RCUS – Free Report) in a report issued on Wednesday, Benzinga reports. HC Wainwright currently has a $20.00 price target on the stock. RCUS has been the topic of several other research reports. Barclays raised their price objective on Arcus Biosciences from $25.00 to […]

Leerink Partnrs upgraded shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) from a hold rating to a strong-buy rating in a research note issued to investors on Wednesday, Zacks.com reports. Several other research firms have also recently issued reports on BEAM. Royal Bank of Canada decreased their price target on shares of Beam Therapeutics from […]

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target upped by equities researchers at JPMorgan Chase & Co. from $100.00 to $105.00 in a report released on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price target points to a potential upside of […]